Lanicemine

DB11889InvestigationalSmall molecule

Lanicemine has been used in trials studying the treatment and basic science of Depression, Major Depressive Disorder, and Treatment Resistant Major Depressive Disorder.

Mechanism: Pharmacologically active on NMDA receptor
Curator reviewed
Formula / weight: C₁₃H₁₄N₂ · 198.269 g/mol (avg)
Code names: AZD-6765

Resolves to

Compound

UNII9TMU325RK3CAS153322-05-5ChEMBLCHEMBL467084PubChem9794203

Structure

InChIKeyFWUQWDCOOWEXRY-ZDUSSCGKSA-NSMILESN[C@@H](CC1=CC=CC=N1)C1=CC=CC=C1

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

679Drug interactionsStructured to mechanism, not free text

9Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which companies are running trials of Lanicemine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account